Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study group

Gou, 2014, Prevalence of driver mutations in non-small-cell lung cancers in the People's Republic of China, Lung Cancer (Auckl), 5, 1 Camidge, 2019, Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study, J Thorac Oncol, 14, 1233, 10.1016/j.jtho.2019.03.007 Yang, 2016, Detection of ALK translocation in non-small cell lung carcinoma (NSCLC) and its clinicopathological significance using the Ventana immunohistochemical staining method: a single-center large-scale investigation of 1, 504 Chinese Han patients, Chin J Cancer Res, 28, 495, 10.21147/j.issn.1000-9604.2016.05.04 Ying, 2019, P1.09-05 ALK Testing in Chinese Advanced NSCLC Patients: A National-Wide Multicenter Prospective Real-World Data Study (The RATICAL Study), Journal of Thoracic Oncology, 14, S497, 10.1016/j.jtho.2019.08.1034 Wu, 2016, Second- and third-generation ALK inhibitors for non-small cell lung cancer, J Hematol Oncol, 9, 19, 10.1186/s13045-016-0251-8 Koivunen, 2008, EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer, Clin Cancer Res, 14, 4275, 10.1158/1078-0432.CCR-08-0168 Barlesi, 2013, Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts), Journal of Clinical Oncology, 31, 8000, 10.1200/jco.2013.31.15_suppl.8000 Kwak, 2010, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, N Engl J Med, 363, 1693, 10.1056/NEJMoa1006448 Shaw, 2013, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med, 368, 2385, 10.1056/NEJMoa1214886 Solomon, 2014, First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med, 371, 2167, 10.1056/NEJMoa1408440 Su, 2017, Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review, J Hematol Oncol, 10, 147, 10.1186/s13045-017-0514-z Khan, 2018, ALK Inhibitors in the Treatment of ALK Positive NSCLC, Front Oncol, 8, 557, 10.3389/fonc.2018.00557 Du, 2018, ALK-rearrangement in non-small-cell lung cancer (NSCLC), Thorac Cancer, 9, 423, 10.1111/1759-7714.12613 Ou, 2020, Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020, JTO Clinical and Research Reports, 1, 1, 10.1016/j.jtocrr.2020.100015 Rothenstein, 2018, ALK inhibitors, resistance development, clinical trials, Curr Oncol, 25, S59, 10.3747/co.25.3760 Clifton, 2018, Actionable fusions in colorectal cancer using a cell-free circulating tumor DNA (ctDNA) assay, Journal of Clinical Oncology, 36, 3507, 10.1200/JCO.2018.36.15_suppl.3507 Rodig, 2009, Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population, Clin Cancer Res, 15, 5216, 10.1158/1078-0432.CCR-09-0802 Hallberg, 2013, Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology, Nat Rev Cancer, 13, 685, 10.1038/nrc3580 2019, [Expert consensus on clinical practice of ALK fusion detection in non-small cell lung cancer in China], Zhonghua Bing Li Xue Za Zhi, 48, 913 Li, 2019, Consistency of ALK Ventana-D5F3 immunohistochemistry interpretation in lung adenocarcinoma among Chinese histopathologists, Zhonghua Bing Li Xue Za Zhi, 48, 921 Novello, 2018, Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study, Ann Oncol, 29, 1409, 10.1093/annonc/mdy121 Nishio, 2018, Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer, Cancer Res Treat, 50, 691, 10.4143/crt.2017.280 Rothenstein, 2014, Managing treatment-related adverse events associated with Alk inhibitors, Curr Oncol, 21, 19, 10.3747/co.21.1740 Chaft, 2018, Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer, Lung Cancer, 122, 67, 10.1016/j.lungcan.2018.05.020 Calio, 2014, ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung, J Thorac Oncol, 9, 729, 10.1097/JTO.0000000000000109 Liang, 2019, Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study, Thorac Cancer, 10, 1521, 10.1111/1759-7714.13090 Vergne, 2016, ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?, Lung Cancer, 91, 67, 10.1016/j.lungcan.2015.11.010 Dragnev, 2014, ALK-rearranged adenosquamous lung cancer presenting as squamous cell carcinoma: a potential challenge to histologic type triaging of NSCLC biopsies for molecular studies, Clin Lung Cancer, 15, e37, 10.1016/j.cllc.2014.01.003 Li, 2017, Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment, J Thorac Oncol, 12, 94, 10.1016/j.jtho.2016.08.145 Conklin, 2013, Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent, J Thorac Oncol, 8, 45, 10.1097/JTO.0b013e318274a83e Li, 2019, [Consistency of ALK Ventana-D5F3 immunohistochemistry interpretation in lung adenocarcinoma among Chinese histopathologists], Zhonghua Bing Li Xue Za Zhi, 48, 921 Ren, 2014, Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer, J Thorac Oncol, 9, e21, 10.1097/JTO.0000000000000013 Takeuchi, 2008, Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts, Clin Cancer Res, 14, 6618, 10.1158/1078-0432.CCR-08-1018 Marchetti, 2016, Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays, Lung Cancer, 99, 11, 10.1016/j.lungcan.2016.06.005 Wang, 2015, EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer, J Thorac Oncol, 10, 1546, 10.1097/JTO.0000000000000668 Cohen, 2020, Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing, J Thorac Oncol, 15, 1000, 10.1016/j.jtho.2020.01.019 Lindquist, 2017, Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer, Oncotarget, 8, 34796, 10.18632/oncotarget.16276 Bruno, 2020, Next Generation Sequencing for Gene Fusion Analysis in Lung Cancer: A Literature Review, Diagnostics (Basel), 10 Li, 2021, Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC, J Thorac Oncol, 16, 404, 10.1016/j.jtho.2020.10.156 Li, 2020, Intergenic Breakpoints Identified by DNA Sequencing Confound Targetable Kinase Fusion Detection in NSCLC, J Thorac Oncol, 15, 1223, 10.1016/j.jtho.2020.02.023 Zhang, 2020, Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC, J Thorac Oncol, 15, 1027, 10.1016/j.jtho.2020.02.007 Davies, 2018, Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples, J Thorac Oncol, 13, 1474, 10.1016/j.jtho.2018.05.041 Benayed, 2019, High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden, Clin Cancer Res, 25, 4712, 10.1158/1078-0432.CCR-19-0225 Choi, 2017, Optimization of RNA Extraction from Formalin-Fixed Paraffin-Embedded Blocks for Targeted Next-Generation Sequencing, J Breast Cancer, 20, 393, 10.4048/jbc.2017.20.4.393 Marczyk, 2019, The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues, BMC Cancer, 19, 1189, 10.1186/s12885-019-6363-0 Kirchner, 2019, RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples, Cancers (Basel), 11, 10.3390/cancers11091309 Li, 2015, Comprehensive evaluation of AmpliSeq transcriptome, a novel targeted whole transcriptome RNA sequencing methodology for global gene expression analysis, BMC Genomics, 16, 1069, 10.1186/s12864-015-2270-1 Li, 2016, Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer, Oncotarget, 7, 8332, 10.18632/oncotarget.6671 Bordi, 2017, Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment, Clin Lung Cancer, 18, 692, 10.1016/j.cllc.2017.04.013 Schwaederle, 2017, Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma, Clin Cancer Res, 23, 5101, 10.1158/1078-0432.CCR-16-2497 Ying, 2013, Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma, Ann Oncol., 24, 2589, 10.1093/annonc/mdt295 Gainor, 2013, ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer, Clin Cancer Res, 19, 4273, 10.1158/1078-0432.CCR-13-0318 Lin, 2018, Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer, J Clin Oncol, 36, 1199, 10.1200/JCO.2017.76.2294 Lin, 2017, Targeting ALK: Precision Medicine Takes on Drug Resistance, Cancer Discov, 7, 137, 10.1158/2159-8290.CD-16-1123 Della Corte, 2018, Role and targeting of anaplastic lymphoma kinase in cancer, Mol Cancer, 17, 30, 10.1186/s12943-018-0776-2 Choi, 2010, EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors, N Engl J Med, 363, 1734, 10.1056/NEJMoa1007478 Jamme, 2019, Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice, Clin Lung Cancer, 20, 10.1016/j.cllc.2019.02.013 Dagogo-Jack, 2016, Crizotinib resistance: implications for therapeutic strategies, Ann Oncol, 27, iii42, 10.1093/annonc/mdw305 Yu, 2019, Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer, Lung Cancer, 127, 19, 10.1016/j.lungcan.2018.11.024 Wu, 2017, Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer, Cancers (Basel), 9, 10.3390/cancers9120164 Kim, 2013, Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer, J Thorac Oncol, 8, 415, 10.1097/JTO.0b013e318283dcc0 Doebele, 2012, Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer, Clin Cancer Res, 18, 1472, 10.1158/1078-0432.CCR-11-2906 Lovly, 2014, Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer, Nat Med, 20, 1027, 10.1038/nm.3667 Hrustanovic, 2015, RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer, Nat Med, 21, 1038, 10.1038/nm.3930 Song, 2019, Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer, Cancer Med, 8, 1551, 10.1002/cam4.2043 Pinto, 2020, Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer, Expert Rev Respir Med, 14, 385, 10.1080/17476348.2020.1721285 Asao, 2017, Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis, Clin Lung Cancer, 18, e251, 10.1016/j.cllc.2016.11.015 Spagnuolo, 2018, Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors, Expert Opin Emerg Drugs, 23, 231, 10.1080/14728214.2018.1527902 Shaw, 2016, Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F, N Engl J Med, 374, 54, 10.1056/NEJMoa1508887 Yoda, 2018, Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer, Cancer Discov, 8, 714, 10.1158/2159-8290.CD-17-1256